CohBar, Inc. (CWBR)
| Market Cap | 85.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -15.27M |
| Shares Out | 50.20M |
| EPS (ttm) | -0.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $1.40 |
| Previous Close | $1.43 |
| Change ($) | -0.03 |
| Change (%) | -2.10% |
| Day's Open | 1.43 |
| Day's Range | 1.39 - 1.44 |
| Day's Volume | 327,634 |
| 52-Week Range | 0.87 - 4.00 |
MENLO PARK, Calif., Dec. 09, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...
MENLO PARK, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...
CohBar, Inc. (CWBR) CEO Steve Engle on Q3 2020 Results - Earnings Call Transcript
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
Bet on these top-ranked stocks with rising P/E to realize outsized gains.
MENLO PARK, Calif., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...
MENLO PARK, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...
Company to host a Key Opinion Leader webinar on the current treatment landscape in IPF, the unmet need, and positive findings from preclinical studies of CohBar's CB5138 Analogs on Friday, Nov...
MENLO PARK, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...
MENLO PARK, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...
MENLO PARK, Calif., Oct. 05, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases a...
MENLO PARK, Calif., Sept. 29, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic disease...
MENLO PARK, Calif., Sept. 10, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic disease...
MENLO PARK, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic disease...
MENLO PARK, Calif., Aug. 28, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat ...
MENLO PARK, Calif., Aug. 26, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat ...
MENLO PARK, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat ...
MENLO PARK, Calif., Aug. 24, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...
CohBar, Inc. (CWBR) CEO Steve Engle on Q2 2020 Results - Earnings Call Transcript
New positive preliminary preclinical results in ARDS model Company to host conference call and webcast at 5:00 p.m. ET
In vivo data demonstrates antifibrotic effects of multiple novel peptide analogs in preclinical models of idiopathic pulmonary fibrosis (IPF) In vivo data demonstrates antifibrotic effects of ...
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
MENLO PARK, Calif., July 07, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...
MENLO PARK, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...
MENLO PARK, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases...
MENLO PARK, Calif., June 02, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases ...
CohBar, Inc. (CWBR) CEO Steve Engle on Q1 2020 Results - Earnings Call Transcript
Former senior executive to continue on CohBar Board of Directors Former senior executive to continue on CohBar Board of Directors
CohBar Looks Undervalued Ahead Of Upcoming Data Readout
Preclinical Testing of CB5064 Analogs Initiated in ARDS Preclinical Testing of CB5064 Analogs Initiated in ARDS
MENLO PARK, Calif., May 01, 2020 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases ...
COVID-19 Pandemic Impact at Clinical Sites Delays Study COVID-19 Pandemic Impact at Clinical Sites Delays Study
CohBar's (CWBR) CEO Steve Engle on Q4 2019 Results - Earnings Call Transcript
Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model Anti-tumor effects demonstrated in vivo in preclinical melanoma immuno-oncology model
New results also confirm anti-inflammatory effect New results also confirm anti-inflammatory effect
CohBar's (CWBR) CEO Steve Engle on Q3 2019 Results - Earnings Call Transcript
MENLO PARK, Calif., Oct. 23, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related dise...
MENLO PARK, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related dise...
MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat age-related dis...
CohBar, Inc. (CWBR) CEO Steven Engle on Q2 2019 - Earnings Call Transcript
CohBar Inc. (CWBR) Interim CEO Philippe Calais on Q1 2019 Results - Earnings Call Transcript
CohBar Inc. (CWBR) CEO Philippe Calais on Q4 2018 Results - Earnings Call Transcript
About CWBR
CohBar, a clinical stage biotechnology company, engages in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes mellitus, cancer, atherosclerosis, cardiovascular, and neurodegenerative diseases, such as Alzheimer's disease. Its lead MBT candidate is CB4211, a novel refined analog of the MOTS-c mitochondrial-derived peptide, w... [Read more...]
| Industry Biotechnology | Founded 2007 |
| CEO Steven B. Engle M.S. | Employees 12 |
| Stock Exchange NASDAQ | Ticker Symbol CWBR |
Analyst Forecasts
According to 3 analysts, the average rating for CohBar stock is "Strong Buy." The 12-month stock price forecast is 6.38, which is an increase of 355.71% from the latest price.